REMEDICA - FOUNDER PATRON


“We are delighted to support the European Business Awards.  As pharmaceutical manufacturers, working for a healthier world, we encourage successful and healthy businesses to participate and be recognised for their achievements through such prestigious awards”
 
CEO, Mr. Charalambos Pattihis
 
Remedica, a member of the Ascendis Health group, is a Cyprus company located in Limassol, with export activities in more than 100 countries. Originally founded in 1960 by Mr. Chris Pattichis, Remedica specialises in the development, production and sale of high-quality, safe and efficacious pharmaceutical products for human use. The company’s product portfolio of more than 300 generic, branded generic and over-the-counter (OTC) products is marketed in more than 100 countries and includes various therapeutic categories such as antineoplastic, antiviral, cardiovascular, central nervous system, gastrointestinal, respiratory tract, dermatological and anti-infective. Currently, Remedica has 5 state-of-the-art factories all of which have been approved by the health authorities of several European Union Member States including those of Cyprus, Germany, United Kingdom and Denmark as well as those of Australia (TGA), Brazil (ANVISA), Japan (PMDA), Iran (IFDA) and many more and are routinely re-inspected in order to ensure continuous compliance. 
 
Remedica out-licenses to both multi-nationals and to smaller companies operating in national markets some o products it develops, a number of which may have early-entry opportunities in some markets. Its product portfolio includes anti-cancer medicines, an area in which the company specialises, products HIV/AIDS, the central nervous system and the cardiovascular system, and has a pipeline covering more therapeutic categories. The efficient  coordination and collaboration  between  the R&D Department, the Regulatory Affairs Department and the Business Development Department make Remedica an ideal partner for companies wishing to in-license generic products from within the EU which offers the following advantages: 
 
  • EU GMP and quality standards
  • No need to repeat analysis and batch release for sales in the EU
  • Timely deliveries
  • The company has a program of continuous investment for the development of new products, and for fin innovative solutions in various fields.

Sponsors